The first detailed report of a specific interaction of CP (caeruloplasmin) with another protein described its complex with LF (lactoferrin) in 2000. Since then, several protein-protein interactions involving CP have been reported, mostly concerning iron-containing proteins. The CP-LF complex was studied thoroughly, and evidence of reciprocal effects of CP and LF was obtained. Another specific interaction investigated in detail occurs between CP and MPO (myeloperoxidase). CP-LF, CP-MPO and CP-LF-MPO complexes were found in sera of patients with inflammation. Modelling in vitro allowed understanding of which structural peculiarities of CP and partners allow the modification of their functions in a complex. The present paper reviews the latest data on complexes of CP with LF and MPO, and advances some suggestions about their role in health and disease.
Basic structural features of CP (caeruloplasmin)
CP (ferro-O 2 oxidoreductase, EC 1. 16.3 .1) is a protein from the α 2 -globulin fraction of human blood serum. This protein belongs to the family of MCOs (multicopper oxidases) and accounts for 95% of plasma copper [1] . hCP (human CP) was first characterized in 1948 [2] . Serum CP is synthesized in the liver; however, its gene is also expressed in the brain, lungs, spleen, testis and some other organs of mammals [3, 4] .
The protein structure of hCP is well studied. Its single chain consists of 1046 amino acids and features internal triplication [5, 6] . Each triplicated unit consists of two domains. As revealed by the X-ray structure obtained at 3.1 Å (1 Å = 0.1 nm) resolution [7] , the molecule of hCP is shaped by six homologous domains arranged in three pairs.
Copper ions in MCOs are classified as three different types depending on their spectroscopic features [8, 9] . CP contains six copper atoms. Almost all of the ligands for copper in the catalytic centre are provided by C-terminal domain 6. One type I Cu 2+ , the only type II Cu 2+ and one type III Cu 2+ are bound there, whereas the other type III Cu 2+ is coordinated by ligands of domain 1. Two more type I (or 'blue') coppers are set apart from the catalytic centre, i.e. in domains 2 and 4 [7, 10] . Understanding structural features of the catalytic centre in CP is important to evaluate changes in the enzyme's activity caused by its interaction with other proteins.
Some physiological functions of CP
Despite intensive studies of CP in the last 60 years, it is believed that only some of its most visible functions have been disclosed. to haemoglobin of reticulocytes. Thus CP acquired its systematic name 'ferro-O 2 oxidoreductase', although it is often termed 'ferroxidase' [13] [14] [15] .
The crucial role of hCP in iron metabolism is supported by reports of acaeruloplasminaemia in patients suffering severe haemosiderosis [16, 17] . This phenotype results from a mutation in the CP gene causing early termination of translation and, consequently, loss of the C-terminal amino acid ligands of coppers in the catalytic centre.
Membrane-bound GPI-CP (glycosylphosphatidylinositol-CP) on the cell surface of astrocytes is essential for iron efflux [18] . GPI-CP co-localizes on astrocytes with iron exporter ferroportin 1, and these proteins probably contact physically, judging by their co-immunoprecipitation [18] . An important role of CP in cellular iron efflux was also evidenced in experiments with hepatocytes and reticuloendothelial cells [19] , and with epithelial cells of duodenum [20] . Interactions of CP with ferritin present another facet of its participation in iron metabolism [21] .
Soon after CP was discovered, Scheinberg and Gitlin [22] described a decrease of its serum concentration in patients with hepatolenticular degeneration or Wilson's disease. That was the first indication of CP's involvement in neurodegenerative processes. Today, biochemical processes underlying neurodegeneration are known better, and the ability of CP to oxidize some organic compounds along with Fe 2+ is noteworthy [23] . Oxidation of brain catecholamines by CP was revealed in early works [24] [25] [26] [27] , but only recently was it demonstrated that, under physiological conditions, some anions increase the activity of CP with non-iron substrates by two orders, whereas Fe 2+ oxidation remains unaffected [28] . This observation indicates that, in the presence of Cl − or other anions, the activity of CP towards non-iron electron donors can be as high as its ferroxidase activity. These data answered affirmatively the question of whether CP can oxidize several substrates simultaneously. Consequently, the observation that CP can oxidize 6-hydroxydopamine seems somewhat important [29] . Its oxidation by CP produces no H 2 O 2 , whereas non-enzymatic oxidation generates toxic oxygen species [30] . Such difference seems to be quite natural, as CP normally accomplishes its reaction of four-electron transfer, water and oxygen being the end-products.
Interaction of CP with other proteins
One of the first detailed reports of the complex of CP with an iron-containing protein described its interaction with ferritin [31] . The authors showed that such complex ensures iron incorporation into ferritin. Within the complex, CP oxidizes Fe 2+ to Fe 3+ , whereas ferritin enhances the ferroxidase reaction. The negatively charged sequence in CP securing its binding to ferritin seems to be the C-terminal stretch of amino acids from residue 1028 to residue 1037.
A year before that study, a report on CP binding to another iron protein, i.e. MPO (myeloperoxidase; E.C. 1.11.1.7), the pro-oxidant enzyme of azurophilic granules of neutrophils, was published [32] . Upon interaction, CP inhibited peroxidase activity of MPO. No particular features of that interaction were described.
By that time, it had been known for decades that unpurified LF (lactoferrin) of human milk had an electrophoretic mobility different from that of pure LF [33] , although the reason for that difference remained unclear.
LF, the breast milk major protein of the transferrin family, is also found in exocrine secretions and in specific granules of neutrophils. It has properties of an immunomodulator, and of a growth and transcription factor. LF has these features because of interactions with various biomolecules and specific binding of transition metals [34] . It is synthesized mostly as iron-free apo-LF and is likely to take up iron in inflammation foci where low pH precludes iron retention by transferrin. The iron-binding capacity of LF seems to underlie its antimicrobial activity realized as sequestering iron ions from the medium, thus preventing their utilization by micro-organisms [35, 36] .
In 2000, we explained why breast milk LF migrates differently in electrophoresis [37] . This protein was shown to bind specifically to CP, a minor component of the milk.
We modelled the interaction between CP and LF in blood plasma on the grounds that LF is likely to egress from neutrophils in inflammation foci, as CP is almost always present [13] . The proteins formed a complex, with 1:1 or 2:1 LF/CP stoichiometry. Interaction of the proteins caused no large structural perturbations as judged by the CD spectrum of their complex. Plasma proteins other than CP did not affect complex formation. Our study showed that the CP-LF complex is not species-specific as human LF intravenously injected in a rat quickly selected the animal's CP to form a complex that circulated in the bloodstream for 5 h.
A K d estimated for the CP-LF complex [37] was later revised [38] . We noticed that binding LF noticeably changes the oxidase activity of CP towards various substrates, such as Fe 2+ , o-DA (o-dianisidine), p-PD (p-phenylenediamine) and DOPA. Two binding sites for LF in the CP molecule were deduced from comparison of substrates' oxidation kinetics with and without LF. When it binds to the first site, the affinity of CP for Fe 2+ and o-DA increases, but remains unchanged towards p-PD and decreases towards DOPA. The oxidation rate of Fe 2+ increases, whereas that of o-DA, p-PD and DOPA decreases. Subsequent LF binding to the second site did not affect iron oxidation, hampered DOPA and o-DA oxidation, and reduced the affinity towards p-PD. The K d for LF binding to the high-affinity site in CP was determined as 13.4 nM, and that for the low-affinity site as 211 nM.
An ionic character of the interaction of CP with LF was documented [39] . Besides, binding to LF does not depend on the presence of copper in CP. It is important that LF hampers proteolytic degradation of CP, usually so sensitive to proteinases. However, even partially proteolysed CP remains within the CP-LF complex. One can suggest that, in an inflammation focus, neither limited proteolysis nor loss of copper prevents interaction of CP and LF.
Soon afterwards, the likely contact sites promoting interaction of CP and LF were suggested for both molecules. In LF, such was considered to be the N-terminal sequence R 2 RRR 5 on account that its structural imitator, the argininerich salmon protamine efficiently dissociates the CP-LF complex [40] .
The same study allowed suggesting probable amino acid sequences in two other proteins forming complexes with CP. Those 144 . Interaction of CP with the latter had been described previously [41] . We synthesized peptide HAGMETTYTV (residues 1028-1037 in CP), which prevents interaction of CP both with protein C and ferritin, but causes no dissociation of the CP-LF complex [42] , hence we looked for another candidate.
As mentioned above, CP is likely to carry two binding sites for LF. Crystallography of CP with attached substrates showed that biogenic amines (e.g. DOPA) are bound in domain 6 (Glu 935 , His 940 , Asp 1025 ), close to the type I copper. Along with these residues, the Fe 2+ -binding site includes Glu 272 [11] . His 667 and Trp 669 in domain 4 that are close to another 'blue' copper, bind synthetic amines (e.g. p-PD) [11] . Our study of LF effects on the oxidase activity of CP [38] combined with other data [7, 43, 44] suggests that the high-affinity site is partly composed of amino acid stretches 50-109 and 929-1012. These stretches in domains 1 and 6 provide ligands for all four copper ions of the catalytic centre that oxidize Fe 2+ . Binding LF probably modifies the active centre of CP, enhancing the ferroxidase reaction, the rate of which remains unaltered when more LF becomes bound, presumably to the low-affinity site in domain 4, reducing the maximum rate of DOPA and o-DA oxidation [38] .
Possible roles for the CP-LF complex have been suggested [37] [38] [39] [40] , although few data on its occurrence in biological fluids had been collected. Among those was the evidence that, in breast milk, it is the CP-LF complex that is so different from the serum CP, not some isoform of CP as proposed before [45] .
However, since a role in inflammation had been proposed for the CP-LF complex, its presence in biological fluids under pathological conditions needed proof. We discovered it in sera and exudates of patients with various inflammatory diseases [44] . An important finding was the presence of the CP-MPO complex and the triple complex CP-LF-MPO along with CP-LF. The first two were present in the majority of samples obtained from patients with various nosologies.
Although CP had been shown to inhibit MPO via direct contact [32] , it was important to detect other possible protein partners of CP from neutrophils (along with LF and MPO) to understand better its role in the inflammatory process. The protein content of neutrophils digested with trypsin was loaded on CP-Sepharose and MS of eluted tryptic fragments detected the presence of eosinophilic cationic protein, cathepsin G, azurocidin, neutrophilic elastase, proteinase 3 and MPO. These cationic proteins have pI values in the alkaline region, unlike pI 4.7 of CP, hence, again, ionic interaction seems highly probable [46] . No potentially interactive species of leucocytes, such as defensins, lysozyme or bactericidal/permeability-increasing protein bound to CP, so a marked selectivity in the pattern of interaction of CP with cationic proteins was proposed.
Meanwhile, studying the CP-MPO complex allowed the identification of the two likely sites of MPO binding along the peptide chain of CP, i.e. between amino acids 50 and 109 in domain 1 and between residues 929 and 1012 in domain 6 [44] . These peptides include residues that co-ordinate all four coppers of the active centre, i.e. In vitro experiments showed that CP only slightly inhibits peroxidase activity of MPO with small aromatic substrates such as guaiacol and orcinol. The interaction of CP and MPO probably creates a steric barrier that precludes binding of aromatic substrates to MPO. The steric barrier is higher for larger substrates; therefore their oxidation by MPO is more strongly altered by CP.
The chlorinating activity of MPO also decreased by 60% in the presence of 0.5 mM CP [47, 48] .
Modelling in vitro complexes of CP with LF and/or MPO raised a question of their stoichiometry. Photon correlation spectroscopy allowed detecting three principal arrangements, i.e. the dimeric complex 1LF-1CP, a trimer 2CP-1MPO and a pentamer 2LF-2CP-1MPO [49] . This supported the notion of two binding sites for CP in the two-subunit MPO molecule, especially since CP should inhibit both its active centres. And vice versa, 1 mol of MPO was enough to activate oxidation of p-PD by 2 mol of CP [47] .
Only non-proteolysed CP could inhibit both activities of MPO, whereas the latter was able to protect CP from proteolysis [47] . The peptide bond most susceptible to proteolysis, namely that connecting domains 5 and 6 in CP, became less vulnerable upon forming the CP-MPO complex. A shift of the Soret band in MPO upon interaction with CP suggested that the sensitive peptide stretch of the latter contacts, or even hides in, the haem pockets of MPO subunits, which was confirmed by a preliminary crystallographic study of the 2CP-1MPO complex.
Thus functional interaction of CP and MPO is efficient only upon 'correct' binding, i.e. the copper protein needs to have an intact peptide chain to contact haem pockets of MPO in order to affect its enzymatic activities, whereas MPO, in turn, shields the most proteinase-sensitive bond in CP providing the integrity needed.
Despite much speculation on the possible role of MPO inhibition by CP, few meaningful findings have been made. Only recently an analysis of 100 plasma samples taken from patients with atherosclerosis revealed the LDL (low-density lipoprotein)-MPO-CP complex in 44 of those, and 33 of those 44 also contained the VLDL (very-low-density lipoprotein)-MPO-CP complex [50] . An important notion is that inhibition of MPO activity by CP is affected by lipoproteins, their affinity for the CP-MPO complex being determined as ∼0.3 nM for VLDL and ∼0.14 nM for LDL.
Conclusions
Summarizing all of the above, one should conclude that, in spite of the longstanding research and very important data collected on CP structure and functions, its physiological activity grounded in the oxidation of various substrates in health and disease, and the fine mechanisms of such activity remain poorly understood. Meanwhile, the details of its interactions with other proteins are beginning to accumulate, indicating that, at least in inflammation, this protein is likely to participate in the regulation of crucial biochemical processes. Unveiling this regulatory pathway may help in the correct positioning of CP in the entire metabolism of the mammalian organism. 
